BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 19751403)

  • 1. Molecular and cell biology of the prototypic arenavirus LCMV: implications for understanding and combating hemorrhagic fever arenaviruses.
    de la Torre JC
    Ann N Y Acad Sci; 2009 Sep; 1171 Suppl 1():E57-64. PubMed ID: 19751403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines.
    Cheng BY; Ortiz-Riaño E; de la Torre JC; Martínez-Sobrido L
    J Virol; 2015 Jul; 89(14):7373-84. PubMed ID: 25972555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arenavirus extinction through lethal mutagenesis.
    de la Torre JC
    Virus Res; 2005 Feb; 107(2):207-14. PubMed ID: 15649566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel antiviral strategies to combat human Arenavirus infections.
    Kunz S; de la Torre JC
    Curr Mol Med; 2005 Dec; 5(8):735-51. PubMed ID: 16375709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of live-attenuated arenavirus vaccines based on codon deoptimization.
    Cheng BY; Ortiz-Riaño E; Nogales A; de la Torre JC; Martínez-Sobrido L
    J Virol; 2015 Apr; 89(7):3523-33. PubMed ID: 25589652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reverse genetics approaches to combat pathogenic arenaviruses.
    de la Torre JC
    Antiviral Res; 2008 Dec; 80(3):239-50. PubMed ID: 18782590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The High Degree of Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses.
    Iwasaki M; Cubitt B; Sullivan BM; de la Torre JC
    J Virol; 2016 Jan; 90(6):3187-97. PubMed ID: 26739049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein.
    Rodriguez-Carreno MP; Nelson MS; Botten J; Smith-Nixon K; Buchmeier MJ; Whitton JL
    Virology; 2005 Apr; 335(1):87-98. PubMed ID: 15823608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. General Molecular Strategy for Development of Arenavirus Live-Attenuated Vaccines.
    Iwasaki M; Ngo N; Cubitt B; Teijaro JR; de la Torre JC
    J Virol; 2015 Dec; 89(23):12166-77. PubMed ID: 26401045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Envelope exchange for the generation of live-attenuated arenavirus vaccines.
    Bergthaler A; Gerber NU; Merkler D; Horvath E; de la Torre JC; Pinschewer DD
    PLoS Pathog; 2006 Jun; 2(6):e51. PubMed ID: 16751848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines.
    Martinez-Sobrido L; de la Torre JC
    Expert Rev Vaccines; 2016 Sep; 15(9):1113-21. PubMed ID: 27118328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans.
    Botten J; Whitton JL; Barrowman P; Sidney J; Whitmire JK; Alexander J; Kotturi MF; Sette A; Buchmeier MJ
    J Virol; 2010 Oct; 84(19):9947-56. PubMed ID: 20668086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies.
    Emonet SE; Urata S; de la Torre JC
    Virology; 2011 Mar; 411(2):416-25. PubMed ID: 21324503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and Mechanism of Action of a Novel Small-Molecule Inhibitor of Arenavirus Multiplication.
    Ngo N; Henthorn KS; Cisneros MI; Cubitt B; Iwasaki M; de la Torre JC; Lama J
    J Virol; 2015 Nov; 89(21):10924-33. PubMed ID: 26292327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mining a Kröhnke Pyridine Library for Anti-Arenavirus Activity.
    Miranda PO; Cubitt B; Jacob NT; Janda KD; de la Torre JC
    ACS Infect Dis; 2018 May; 4(5):815-824. PubMed ID: 29405696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.
    Cai Y; Ye C; Cheng B; Nogales A; Iwasaki M; Yu S; Cooper K; Liu DX; Hart R; Adams R; Brady T; Postnikova EN; Kurtz J; St Claire M; Kuhn JH; de la Torre JC; Martínez-Sobrido L
    mBio; 2020 Feb; 11(1):. PubMed ID: 32098811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residues K465 and G467 within the Cytoplasmic Domain of GP2 Play a Critical Role in the Persistence of Lymphocytic Choriomeningitis Virus in Mice.
    Iwasaki M; Ng CT; Cubitt B; de la Torre JC
    J Virol; 2016 Nov; 90(22):10102-10112. PubMed ID: 27581982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neutralization test for lymphocytic choriomeningitis virus for distinguishing between two arenavirus infections in Argentina].
    Ambrosio AM; Riera L; Saavedra MC; Sottosanti JJ
    Rev Argent Microbiol; 2001; 33(4):235-40. PubMed ID: 11833256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease.
    Urata S; Yun N; Pasquato A; Paessler S; Kunz S; de la Torre JC
    J Virol; 2011 Jan; 85(2):795-803. PubMed ID: 21068251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reverse Genetics Approaches to Control Arenavirus.
    Martínez-Sobrido L; Cheng BY; de la Torre JC
    Methods Mol Biol; 2016; 1403():313-51. PubMed ID: 27076139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.